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Gastroprotective effects of the isopropanol extract 
of Artemisia princeps and its gastroretentive floating tablets 
on gastric mucosal injury
In this study, we investigated the gastropro-
tective effect of an isopropanol extract from 
the aerial parts of Artemisia princeps (IPAP) 
and developed a gastroretentive floating tab-
let of IPAP (IPAP-FR) for maximized local 
gastroprotective effects. Pre-treatment with 
IPAP ameliorated the gastric mucosal hemo-
rrhagic lesions in ethanol/HCl- or indometh-
acin-treated rats. IPAP decreased mucosal 
hemorrhage of gastric ulcers induced by 
ethanol or indomethacin plus pyloric liga-
tion in rats. The optimized floating tablet, 
IPAP-FR, floated on medium surface with 
more sustained eupatilin release compared 
to the non-floating control tablet. X-ray pho-
tographs in beagle dogs showed that IPAP-
FR was retained for > 2 h in the stomach. In 
the ethanol-induced gastric ulcer rat model, 
the gastric hemorrhagic lesion was improved 
more substantially with IPAP-FR compared 
to the non-floating control tablet. Based on 
these data, our data suggest that IPAP-FR has 
an improved therapeutic potential for the 
treatment of gastric ulcer.
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Peptic ulcer is a disturbance in the lining of the esophagus, stomach, or small intes-
tine, manifested by irritating symptoms such as burning pain, bloating, heartburn, nau-
sea, or vomiting (1). It is a common and recurrent disease, affecting 10 % of the general 
population globally. It is caused by disturbances in the equilibrium between the gastric 
aggressive factors (acid, pepsin, and Helicobacter pylori) and the mucosal defensive factors 
(gastric mucus and bicarbonate secretion, prostaglandins, innate resistance of mucosal 
cells) (2). Drugs commonly used in the treatment of gastric ulcers are antacids, anticholin-
ergics, proton pump inhibitors, and H2-receptor antagonists. However, current therapy of 
peptic ulcers may fail due to inadequate effectiveness, hypersensitivity, or adverse effects 
such as gynecomastia, impotence, arrhythmia, and hematopoietic changes although rare 
(3). This has led to the need to develop new antiulcer drugs, so the search for novel mole-
cules has been extended to medicinal plants, which can offer better protection and reduce 
relapses (4).
Drug delivery systems with prolonged gastric residence time (GRT) may provide an 
innovative and advanced therapeutic option for gastric ulcers by retaining the drug for a 
longer period of time in the stomach (5). Several strategies are used to extend GRT of dos-
age forms, such as, superporous hydrogel, high-density (sinking), mucoadhesive, expand-
able, bioadhesive, magnetic, or low density (floating) systems (6). Among them, floating 
drug delivery systems allow the formulation to remain buoyant in the stomach without 
affecting the gastric emptying rate and thereby enable prolonged release of the drug, mak-
ing it potentially more effective to treat gastric ulcers compared to conventional dosage 
forms. Several floating system approaches have been designed and developed, including: 
the gas generating system, raft forming system, colloidal gel barrier system, microporous 
compartment system, floating microsphere system and the low density system (7).
Artemisia princeps Pampanini (Asteraceae), commonly known as ‘Sajabalssuk’ in Ko-
rea, is commonly used for the management of various diseases including colic pain, diar-
rhea, uterine metrorrhagia, metritis, vomiting, ulcers, dysmenorrhea, microbial infections, 
and cancer (8). It may be used alone for the management of mild diseases or in combination 
with other medicinal herbs and/or conventional evidence-based drug therapy for the mana-
gement of moderate to severe diseases as a traditional medical treatment option in Asian 
countries (8). It is well known that Artemisia possesses many biological active phytochemi-
cals such as flavonoids, alkaloids, phenols, steroids, and essential oils. Eupatilin (5,7-dihy-
droxy-3 ,́4 ,́6 trimethoxy flavone) is the main active compound isolated from Artemisia 
plants and has a variety of biological activities, such as anti-inflammatory, anti-oxidative, 
cytoprotective, and pro- or anti-apoptotic effects (9, 10). Many Artemisia species have bio-
logical activities, such as anti-inflammatory, anti-bacterial, anti-asthmatic, anti-cancerous, 
and neuroprotective activities. Ethanol extract of A. asiatica has been reported to possess 
anti-oxidative and anti-inflammatory effects on experimentally induced gastrointestinal 
damage as well as hepatic and pancreatic lesions (11, 12). Based on these pharmacological 
properties, the first antipeptic ulcer drug prepared from ethanol extracts of A. asiatica, 
StillenTM, was developed to treat patients with gastric mucosal ulcers and is commercially 
available in South Korea and other Asian countries (13). One of the problems associated 
with the ethanol extracts of Artemisia is the risk of coagulopathy due to dicoumarol in 
ethanol extracts (14). To minimize this risk, isopropanol extract was chosen in our current 
study because dicoumarol is not extracted if isopropanol is used as the extraction solvent. 
Furthermore, compared to ethanol extract, the isopropanol extract of A. princeps contains 
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more eupatilin and jaceosidin, the major active flavonoids in Artemisia. Therefore, the 
isopropanol extract of A. princeps is expected to have more potent pharmacological actions 
and fewer toxic or unwanted side effects. Although various biological activities of A. prin-
ceps have been demonstrated, including anti-cancer, immunomodulatory, anti-oxidant, 
anti-diabetic and antiatherosclerotic activities (15, 16), no report has been published on 
gastroprotective or anti-ulcer activities of isopropanol extracts from the aerial parts of A. 
princeps (IPAP). In this study, we investigated the gastroprotective potential of IPAP in rats 
with ethanol and HCl or indomethacin-induced gastric ulcer with or without pylorus liga-
tion. In addition, we have applied floating drug delivery systems to IPAP to enhance its 
pharmacological potency by improving gastric retention.
EXPERIMETAL
Chemicals and reagents
Sodium bicarbonate was obtained from Dr. Paul Lohmann (Lüneburg, Germany). 
Hydroxypropylmethylcellulose (HPMC) was purchased from Kanto Chemical (Japan). 
HPLC-grade formic acid and acetonitrile were purchased from Wako (Japan) and from 
Fisher Scientific Korea (South Korea), respectively. Hydroxypropyl celluloses, hypromellose 
(Metolse 60 SH-10,000), Carbomer, calcium silicate (Florite-RE), lactose hydrate (Pharma-
tose 100M), croscarmellose sodium, microcrystalline cellulose (Comprecel D101), sodium 
carboxymethylcellulose (CMC-Na), ethanol, indomethacin, and sodium lauryl sulfate 
(SLS) were purchased from Sigma Chemical Co. (USA). Reference compounds of chrolo-
genic acid (purity ≥ 98.0 %), luteolin (purity ≥ 97.0 %) and 3,5-di-caffeoylquinic acid (purity 
≥ 95 %) were purchased from Sigma-Aldrich (USA). Reference compounds of jaceosidin 
(purity > 95 %) and eupatilin (purity > 98 %) were purchased from Chengdu Biopurify 
Phytochemicals Ltd (China).
Preparation of EAP and IPAP
Aerial parts of Artemisia princeps Pampanini were dried (2.0 kg), cut, and extracted in 
20 volumes of isopropanol at room temperature for 48 h. Extracted solutions were filtered 
and the filtrates were evaporated at 60 °C. IPAP was prepared by concentrating the ex-
tracted solutions to one-twentieth (100 g, m/m) of the initial herbal weight. IPAP was then 
tested according to an in-house quality assurance procedure for physicochemical proper-
ties and microorganism and heavy metal contaminants. A standardized 95 % ethanol ex-
tract from the aerial parts of A. princeps (EAP) was obtained from Dongbang FTL (Seoul, 
Korea).
UPLC-PDA-ESI-MS analysis
A Waters AcquityTM H-class ultra-performance liquid chromatography (UPLC) sys-
tem (Waters Corp., Milford, USA) equipped with a photo diode array (PDA) detector and 
a JMS-T100TD (AccuTOF) (JEOL Ltd., Tokyo, Japan) spectrometer with an electrospray 
ionization (ESI) source were used for chromatographic and mass spectrometric (MS) analy-
ses. For the UPLC-MS analysis, IPAP (5 mg) was dissolved in methanol (1 mL). Reference 
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standard compounds (0.5 mg mL–1) were dissolved separately in methanol and then mixed 
together into a cocktail solution, which was used as a reference standard solution. The 
sample solution and reference standard solution were filtered through a 0.2-μm PTFE sy-
ringe filter (Whatman, UK) before injection into the UPLC system.
Table I. Compositions of the IPAP tablet and various floating tablets (F1-F4) consisting of different ingredients
Process Object Ingredient IPAP tablet
Floating tablets




































































































Total (mg) 335 500 560 304 356
a Numbers in parentheses indicate the content (%).
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Animals
Male Sprague-Dawley rats weighing 230-300 g and male beagle dogs weighing 9–10 
kg were obtained from Orient Bio (Seoul, Korea) and maintained under constant labora-
tory conditions and (temperature: 20 ± 2 °C, humidity: 40–60 %, light/dark cycle: 12 h). All 
experiments were conducted in accordance with the Standard Operation Procedure for 
Animal Care and Experiments (SOP-ANC) of the Korea Animal Medical Science Institute. 
All animal experimental protocols were approved by the Animal Ethical Committee of 
Korea of the Animal Medical Science Institute (189, Donggureung-ro, Guri-si, Gyeonggi-
do, Republic of Korea); Approval number: KAMSI IACUC 15-KE-048, KAMSI IACUC 15-
KE-050, KAMSI IACUC 15-KE-132, KAMSI IACUC 15-KE-132).
Ethanol-induced ulcer in rats
IPAP and EAP were dissolved in 1 % HPMC solution in distilled water before use. 
IPAP (30, 60, or 90 mg kg–1), EAP (60 mg kg–1), or vehicle (1 % HPMC) was administered 
orally to rats (n = 10/group) after fasting for 24 h. One hour after the tested sample treat-
ment, the rats received intragastrically 5 mL kg–1 of 60 % ethanol in 150 mM HCl via the 
intragastric route to induce acute gastric ulcer. One hour later, the rats were sacrificed by 
cervical dislocation; the stomachs were then removed and the area of the lesions was mea-
sured. Percent of lesion inhibition was estimated by:
 lesion inhibition (%) = (lesion area of vehicle control group – 
 lesion area of test group) / (lesion area of vehicle control group) ´ 100
Indomethacin-induced ulcer in rats
One hour after the tested sample treatment, rats received indomethacin in 0.5 % CMC-
Na solution in distilled water (100 mg kg–1, p.o.) to induce acute gastric ulcer. Six hours 
later, the rats were sacrificed by cervical dislocation, the stomachs were removed and then 
the area of the lesions was measured.
Ethanol plus pyloric ligation-induced ulcer rat model
Acute gastric damage was induced with 70 % ethanol administered via the intragas-
tric route to rats after fasting for 24 h. Thirty min later, pyloric ligation was performed 
under anesthesia with intramuscular injection of 15 mg kg–1 tiletamine/zolazepam (Zoletil50®; 
Virbac Lab., France) and 9 mg kg–1 xylazine (Rompun®; Bayer, Germany). The abdomen 
was opened below the xiphoid process, and the pyloric end of the stomach was ligated 
avoiding injuries to the adjacent blood vessels. Afterwards, the ligated stomach was return-
ed to its original position and the abdomen was sutured. After 30 min, IPAP (90 mg kg–1) or 
rebamipide (100 mg kg–1) was administered orally. After 10 min or 120 min, the rats were 
sacrificed by cervical dislocation, the stomachs were removed, and the area of the lesions 
was measured.
Indomethacin plus pyloric ligation-induced ulcer rat model
To induce gastric damage, 100 mg kg–1 indomethacin (in 0.5 % CMC-Na) was orally 
administered to the rats after fasting for 24 h. After 4 h, gastric pylorus was ligated under 
anesthesia using the same procedure as described above.
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Preparation of IPAP or IPAP FR tablets
IPAP tablets were prepared by the conventional wet granulation method (17). IPAP (60 
mg) and MicroceLac 100 (246 mg, as a filler) were kneaded with ethanol in a high-speed 
mixer and granulated. Granules were dried using a fluidized bed dryer (inlet temp. 50 ± 
10 °C, product temp. 35 ± 5 °C, drying time 20 min). Dried granules were sieved using an 
oscillator (20 mesh). Moisture content was measured using a moisture analyzer (< 2.0 %). 
Granules were mixed with additives (7 mg of Eudragit® E100 as an erosion polymer, 12 mg 
of croscarmellose sodium as a disintegrating agent and 5 mg of silicon dioxide Aerosil® 
200 as a glidant) and then pressed to form capsule-shaped tablets using a single-punch 
tablet pressing machine (Sejong, Korea). Tableting force was 300–500 kg/cm2, tablet hard-
ness was 5.0–10.0 kp and dimensions were 13.0 × 7.0 × 4.0–4.8 mm.
IPAP gastroretentive floating tablets were prepared so that IPAP, hydroxypropyl cel-
lulose, lactose hydrate, microcrystalline cellulose, sodium bicarbonate, croscarmellose 
sodium and calcium silicate were kneaded with ethanol in a high-speed mixer and granu-
lated. Granules were sieved using an oscillator (20 mesh) and were then dried using a 
fluidized bed dryer (inlet temp. 70 ± 10 °C, product temp. 40 ± 5 °C, drying time 20 min). 
Moisture content was measured using a moisture analyzer (< 2.0 %). Dried granules were 
sieved with the aid of an oscillator (30 mesh). Granules were mixed with carbomer, hypro-
mellose, magnesium stearate or talc using a V-mixer, and then pressed to form tablets 
using the single-punch tablet pressing machine. The formulation of gastroretentive float-
ing tablets (F1, F2, F3, F4) was optimized by adjusting the amounts of ingredients. The four 
formulations of gastroretentive floating tablets (F1, F2, F3, F4) were prepared using varied 
concentrations of ingredients, as shown in Table I.
Assay of eupatilin tablets in pH 1.2 dissolution media (Solubility test)
Each gastroretentive floating tablet (F1-F4) was put into a vial containing 20 mL of 
hydrochloric acid buffers (pH 1.2). Vials were kept at 37 °C and rotated at a speed of 40 rpm 
using a dialysis tester for 24 h. Solutions were then passed through a 0.45-μm filter mem-
brane, and the amount of eupatilin (representative standard of tested tablets) was mea-
sured using high-performance liquid chromatography (HPLC). HPLC analysis of eupati-
lin released from the tablets in solutions was conducted using a Waters Alliance HPLC 
system (Massachusetts, USA), which consisted of an e2695 pump and 2498 UV/Vis detector. 
Calibration curve was constructed by plotting various concentrations of eupatilin (0.04–4 
μg mL–1) with a correlation coefficient of > 0.999.
Dissolution rate of tablets at pH 1.2 (Determination of disintegration time)
The release of eupatilin from IPAP gastroretentive floating (F1 to F4) or IPAP tablets 
was investigated using the USP paddle method. The tablet was added to the dissolution 
medium (900 mL of acidic buffer solution at pH 1.2 supplemented with 0.5 % SLS) without 
a sinker and rotated at a speed of 50 rpm at 37.0 ± 0.2 °C (n =12). Samples were collected at 
specific time intervals (5, 10, 15, 30, 45, and 60 min) to analyze the amount of eupatilin us-
ing HPLC.
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In vivo buoyancy study
Six male beagle dogs (9–10 kg) were used to assess in vivo floating behavior. They were 
divided into two groups where one received IPAP tablets while the other received IPAP-FR 
tablets. Animals were fasted overnight and were only allowed free access to water. For the 
radiographic study, an IPAP tablet and IPAP-FR tablets containing 50 mg barium sulfate as 
a radio opaque agent were prepared. An abdominal radiograph in the standing position was 
taken every 5 min after administration of the tablet until the absence of radio-opaque mate-
rial in the stomach using an X-ray machine (Arcadis Varis, Simens, USA).
Preparation of mini-IPAP FR or IPAP tablet formulae for the in vivo test
The same formula (Table I) was prepared, each tablet containing 22.5 mg of active 
ingredients (IPAP). Weights of mini-IPAP FR and mini-IPAP tablets were 89.0 mg and 125.6 
mg, respectively. Simply, granules were pressed to produce tablets using the single-punch 
machine (2 mm diameter/tablet, Young Chang Punch Co., Ltd., Korea).
Therapeutic antiulcer activities of mini-IPAP-FR or IPAP tablets in ethanol-induced 
gastric ulcers in the rat model
Gastric damage was induced with 70 % ethanol administered via the intragastric route 
(18) to rats after fasting for 24 h. A mini-IPAP-FR or IPAP tablet was encapsulated in a size 
9 gelatin capsule (Torpac, USA), and each capsule contained 22.5 mg of active ingredients 
(IPAP). A gelatin capsule containing IPAP-FR (90 mg kg–1), IPAP tablet (90 mg kg–1) or ve-
hicle (only gelatin capsule) was administered orally to rats (n = 6/group) by oral gavage 
(Torpac, USA). After 2 h, rats were sacrificed by cervical dislocation, the stomachs were 
removed, and the area of the lesions was measured.
Statistical analysis
The results are presented as mean ± standard error of the mean (SEM) of animals per 
group. Statistical evaluation of the data was performed using one-way analysis of variance 
(ANOVA) followed by the post-hoc Dunn’s test. P values lower than 0.05 were considered 
significant. All statistical tests were conducted using the Graph Pad Prism (California, USA).
RESULTS AND DISCUSSION
Phytochemical identification of IPAP by UPLC-PDA-ESI-MS
The UPLC chromatogram of IPAP monitored at 320 nm is shown in Fig. 1. Five peaks 
(chlorogenic acid, eupatilin, 3,5-dicaffeoylquinic acid, luteolin, and jaceosidin) were identi-
fied by direct comparison with the corresponding reference standards (Fig. 1). Detailed MS 
data and absorption maxima data of these peaks are listed in Table II. These compounds 
have been previously identified in Artemisia princeps (19, 20). The results show that the 
botanical origin of the raw material was re-confirmed by chemical fingerprinting, and the 
major components of the extract were anti-oxidant phenolic compounds such as eupatilin, 
jaceosidin, and 3,5-dicaffeoylquinic acid. IPAP was analyzed for major flavonoids, and 
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eupatilin and jaceosidin were present at concentrations of 1.89 % (in-house quality assur-
ance criterion: 0.8–2.4 %) and 0.72 % (in-house quality assurance criterion: 0.25–0.67 %), 
respectively, by HPLC (data not shown). Eupatilin and jaceocidin concentrations in EAP 
were 1.10 and 0.48 %, respectively.
Gastroprotective effect of orally administered IPAP in the ethanol/HCl-  
or indomethacin-induced rat ulcer models
The current study reports for the first time that IPAP had in vivo antiulcer activity in the 
ethanol/HCl- and indomethacin-induced gastric ulcer model (n = 10) in order to compare its 
pharmacological efficacy for EAP. Oral administration of ethanol accelerated gastric muco-
Fig. 1. UPLC chromatogram of: a) IPAP and b) reference standard solution.
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sal necrosis and apoptosis due to damaged gastric mucosal defense system and, consequent-
ly, produced acute hemorrhagic gastric erosions (21). Thus, the ethanol-induced gastritis in 
vivo model is considered a reliable tool to evaluate gastritis pathogenesis (22). To investigate 
the in vivo ability of IPAP to prevent ethanol/HCl-induced acute gastric ulcer in rats, we 
measured the total mucosal hemorrhagic lesion area after oral administration of IPAP (30, 
60 or 90 mg kg–1) to rats. No mortality of rats at a high dose of 1 g kg–1 of body mass was 
observed in a toxicity test, indicating that IPAP was well tolerated by experimental rats. As 
shown in Table III, a single dose of 60 % ethanol in 150 mmol L–1 HCl (5 mL kg–1, p.o.) se-
verely increased mucosal hemorrhagic lesions to 133.9 ± 12.4 mm2 compared to the vehicle-
treated control group (0 mm2), which is consistent with the results of a previous report (23). 
Pretreatment with IPAP (30, 60 or 90 mg kg–1, p.o.) showed significant (p < 0.05) reduction in 
mucosal hemorrhagic lesions with inhibition of 68, 88.8, or 93 %, respectively, compared to 
the ethanol/HCl alone-treated group. Percent inhibition of mucosal hemorrhagic lesions was 
higher in rats pretreated with 60 mg kg–1 of IPAP (88.8 %) compared to those with EAP (79.1 
% at 60 mg kg–1), but statistical significance was not reached. Here, we have clearly demon-
strated that the ethanol/HCl-induced group produced the expected characteristic intralumi-
nal bleeding in the glandular portion of the stomach, while pretreatment with IPAP signifi-
cantly protected rats with ulcers induced by ethanol and HCl from intraluminal bleeding. 
This result suggests that IPAP exerted an antiulcer effect associated with cytoprotective ac-
tivity. To confirm the gastroprotective effect of IPAP, we evaluated its effect on the indometha-
cin-induced gastric ulcer model. Non-steroidal anti-inflammatory drugs (NSAIDs) cause 
gastric ulcers by oxidative damage and prostaglandin (PG) deficiency (24). According to a 
previous study (25), administration of indomethacin significantly induced ulcerative lesions; 
therefore, we used this method to induce ulcer lesions in rats. As shown in Table III, after 
Table III. Gastroprotective effects of IPAP on ethanol- or indomethacin-induced gastric ulcers in rats
Treatment (p.o.) Dose (mg kg–1)  Hemorrhagic lesion (mm2) Inhibition (%)
Vehicle 0 0 –
IPAP 90 0 –
Ethanol/HCl
– 0 133.9 ± 12.4
+ IPAP
30 46.9 ± 7.9a 65.0
60 15.0 ± 4.3a 88.8
90 9.4 ± 3.2a 93.0
+ EAP 60 28.1 ± 5.0a 79.1
Indomethacin
– 0 31.3 ± 7.4 0
+ IPAP
30 14.4 ± 3.7a 54.0
60 10.3 ± 1.7a 67.1
90 15.0 ± 3.5a 52.1
+ EAP 60 20.0 ± 6.0 36.1
Data are presented as mean ± SEM (n = 10/group).
a p < 0.05 vs. the ethanol/HCl-induced group or indomethacin-induced group.
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administration of indomethacin (100 mg kg–1, p.o.), the area of observed ulcerative lesions 
was 31.3 ± 7.4 mm2. IPAP (30, 60, or 90 mg kg–1) or EAP (60 mg kg–1, as a positive control) in-
hibited mucosal hemorrhagic lesions by 54, 67.1, 52.1, or 36.1 %, respectively, compared to 
their respective indomethacin-induced groups. This result indicates the gastroprotective 
potential of IPAP in the indomethacin-induced ulcer model. Pretreatment with EAP (60 mg 
kg–1, p.o.) decreased the mucosal hemorrhagic lesions caused by indomethacin (20.0 ± 6.0 
mm2); however, the result lacked statistical significance. Therefore, the gastroprotective ef-
fect of IPAP was observed to be more potent than that of EAP at the same dose of 60 mg 
kg–1. This result indicated that IPAP could be administered together with NSAIDs such as 
indomethacin in order to minimize adverse effects of NSAIDs on the gastric mucosa.
Therapeutic effects of IPAP on gastric ulcers induced by ethanol or indomethacin plus 
pyloric ligation in rats
Ligation of the pyloric end of the stomach causes accumulation of gastric acid in the 
stomach and produces ulcers. These ulcers result from autodigestion of the gastric mucosa, 
Fig. 2. Therapeutic effects of IPAP on the ethanol or indomethacin plus pyloric ligation-induced gastric 
ulcers in rats. Pyloric ligation was done 30 min after oral administration of 60 % ethanol (5 mL kg–1, a 
and b) or 4 h after oral administration of indomethacin (100 mg kg-1, p.o. c and d). After 30 min, rats were 
treated with IPAP (90 mg kg-1, p.o.) or rebamipide (Reba, 100 mg kg–1, p.o., positive control) for 10 min or 
120 min. Gastric lesions in the stomach were measured (a and c) and photographs of the lesions were 
taken (b and d). Data are presented as means ± SEM (n = 10/group). * p < 0.05 vs. the ethanol- or indo-
methacin-induced group. $ p < 0.05 vs. group treated with indomethacin plus rebamipide.
a)                                                           b)
c)                                                           d)
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leading to a breakdown of the gastric mucosal barrier (26). In the antiulcer activity test 
using the ethanol plus pyloric ligation-induced ulcer rat model (Fig. 2a,b), the vehicle-
treated control group and only IPAP-treated group (90 mg kg–1, p.o.) did not show any 
significant gastric hemorrhagic lesions (0 mm2). Intragastric administrations of ethanol 
plus pyloric ligation induced gastric ulcer with a significant increase in mucosal hemor-
rhagic lesions in rats (61.3 ± 6.4 mm2; 10 min or 63.8 ± 6.6 mm2; 120 min). After post-treat-
ment with IPAP (90 mg kg–1, p.o.) or rebamipide (100 mg kg–1, p.o. as a positive control) for 
10 or 120 min, mucosal hemorrhagic lesions were significantly suppressed compared to 
lesions without treatment in the ethanol-induced ulcer group (p < 0.05, Fig. 2a).
In the antiulcer activity test using the indomethacin plus pyloric ligation-induced 
ulcer rat model (Fig. 2c,d), the mucosal hemorrhagic areas of only indomethacin adminis-
tered groups were 32.7 ± 3.6 mm2 (10 min group) and 31.2 ± 2.9 mm2 (120 min group), re-
spectively. Post-treatment with IPAP (90 mg kg–1, p.o.) or rebamipide (100 mg kg–1, p.o.) 
significantly reduced the mucosal hemorrhagic lesions caused by indomethacin plus pyloric 
ligation in rats. Notably, the therapeutic effect of the 120-min IPAP-treated group was sig-
nificant (p < 0.05) compared to the rebamipide-treated group in indomethacin plus pyloric 
ligation-induced ulcer rats. Macroscopically, severe visible lesions induced by ulcer to the 
gastric mucosa appeared as elongated bands of hemorrhage. However, the IPAP post-treat-
ment group had considerably reduced gastric lesions in the mucosa compared to the ulcer-
induced group without post-treatment. The vehicle-treated control rats or those given 
IPAP only (90 mg kg–1, p.o.) did not develop any gastric hemorrhagic lesions (Fig. 2b,d). Our 
results confirm that IPAP has cytoprotective and therapeutic properties against various 
stimuli and might have anti-secretory properties that reduce secretion of gastric aggres-
sive factors, such as acid and pepsin. However, further study will be needed to determine 
the mechanisms of IPAP action.
Dissolution rates of gastroretentive floating tablets of IPAP in pH 1.2 dissolution media
Use of a gastroretentive system that releases drugs in a sustained manner is likely to 
enhance the gastroprotective effects of IPAP. Therefore, we have formulated various gas-
troretentive floating tablets (F1-F4) of IPAP by using an effervescent floating matrix system, 
which was designed to cause the tablet to float in the gastric fluid and release eupatilin 
continuously. The drugs were formulated using sodium bicarbonate as a gas-generation 
agent in combination with acidic media of the stomach, carbomer and hypromellose as 
controlled release agents, and croscarmellose sodium as a disintegrating agent (27). Com-
positions of gastro-retentive floating tablets (F1-F4) are given in Table I. All gastro-reten-
tive tablets F1-F4 contained 90 mg of IPAP. The non-floating IPAP tablet was prepared by 
the conventional wet granulation method without the previously mentioned specialty ex-
cipients. To optimize the tablet manufacturing process, we tested two methods: direct 
compression and wet granulation methods. Since the direct compression method was 
problematic due to inability of IPAP to mix homogeneously due to the low density of IPAP 
(< 0.7 g mL–1), the wet granulation method was applied using ethanol and hydroxypropyl 
cellulose as the liquid binding solution.
Physicochemical characteristics of the IPAP tablet and gastroretentive floating tablets 
(F1-F4) are summarized in Table IV. F1 formulation was composed of granules, produced 
with IPAP as an active ingredient, microcrystalline cellulose and lactose hydrate as filler, 
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and sodium bicarbonate as a gas-generating agent, but eupatilin was not released from 
the F1 tablet in the dissolution test due to lack of disintegration (Fig. 3). Therefore, cros-
carmellose sodium was added as a disintegrating agent to the F2 formulation. When dis-
integration continues and the tablets become smaller, the tablets are expected to float. The 
problem of F2 formulation was the inability of the tablet to float because of high density. 
F3 formulation was developed to reduce density by decreasing the amount of lactose hy-
drate and microcrystalline cellulose and to solubilize by adding calcium silicate as a lu-
bricant. Microcrystalline cellulose was added to the F3 formulation to allow calcium sili-
cate to adsorb the IPAP. F3 tablets showed a floating time of 10 min, but disintegrated 
within 30 min. For the purpose of delaying disintegration, 30 mg carbomer and 20 mg 
hypromellose were added as controlled release agents to formulation F3 to develop for-
mulation F4. Tablet F4 floated for 12 min and disintegrated within 120 min, tablet F4 first 
swelled at the beginning of the dissolution test and then floated for 12 min. Solubility of 
Fig. 3. Dissolution rates of eupatilin from gastoretentive floating tablets of IPAP compared to the IPAP 
tablet (n = 12) in pH 1.2 dissolution media. Release studies of the tablets were carried out using the USP 
paddle method, as described in the Method section. The formulations used are detailed in Table I.
Table IV. The physicochemical properties of IPAP and F1-F4
IPAPa 
tablet F1 F2 F3 F4
a
Mass (mg) 335 500 560 307 354
Friability (%) 0.5 0.2 0.8 1.2 0.3
Thickness (mm) 4.3 4.6 4.9 4.1 4.5
Content of eupatilin (%) 98.8 98.9 99.2 99.4 99.3
Disintegration time (min) 10 - 60 30 120
Floating timeb (min) - - 45 10 12
Solubility (μg mL–1) 30.0 45.5 48.6 76.4 68.1
a IPAP-FR
b floating time – time for tablets to float above the surface
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these tablets was studied in pH 1.2 USP buffer solutions using eupatilin as an active in-
gredient. Solubility of tablet F4 was 2.3 times (68.1 μg mL–1) higher compared to the IPAP 
tablet (30.0 μg mL–1).
Fig. 3 shows eupatilin release in the dissolution test of F1, F2, F3, F4, or the control 
IPAP tablet in pH 1.2 dissolution media. Addition of croscarmellose and/or hydropropyl 
cellulose into the matrix (F2, F3, and F4) increased the dissolution rate compared to sodium 
bicarbonate addition only (F1). Controlled release agents (carbomer and hypromellose) in 
formulation F4 markedly extended dissolution profiles compared to tablets prepared with-
out these agents (F2 and F3). Disintegration time of tablet F4 was time-dependently sus-
tained up to 60 min compared to those of IPAP (F1, 10 min), F2 (60 min) and F3 (30 min), 
whereas F1 did not show any integration up to 60 min (Fig. 3). Collectively, formulation F4 
was expected to float in the stomach and show local effects on the gastric mucosa. There-
fore, formulation F4 (IPAP-FR) was selected as the optimized gastroretentive floating tablet 
of IPAP and was expected to show more potent pharmacological actions.
X-ray photographs taken after administering the IPAP- FR tablet to a beagle dog
X-ray is currently a very popular evaluation method for floating dosage forms. It helps 
locate dosage forms in the gastrointestinal tract and enables one to predict and correlate the 
gastric emptying time and the passage of dosage forms through the gastrointestinal tract. 
Here, the inclusion of 50 mg of barium sulfate as a radio-opaque material into a tablet en-
abled it to be visualized by X-rays (28, 29). To examine whether the IPAP-FR could remain 
floating in the stomach, evaluation using an X-ray apparatus was conducted in six male 
beagle dogs in the fasting state. Fig. 4 shows the radiographic images taken at different time 
periods after administration of the barium sulfate-loaded IPAP-FR and IPAP tablets to beagle 
dogs. IPAP tablet was observed to be buoyant on the fluid in the stomach at 5 min and then 
Fig. 4. Radiograph images of the: a) IPAP tablet (at 5 and 10 min) and b) IPAP-FR tablets (at 10, 30, 60, 
and 120 min) after oral administration to beagle dogs in the fasting state. Standing radiographs of the 
abdomen were taken 5 min after the ingestion of the tablet and then every 5 or 10 min, until the ab-
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disappear 10 min after oral administration. However, IPAP-FR continued floating in the 
stomach for at least 2 h. Therefore, the IPAP-FR delivery system was suggested to be useful 
to attain longer sustained release of drugs in the fasting state. Since the gastric motility and 
stomach emptying of both dogs and humans show little difference (30), it could be deduced 
the IPAP-FR could show increased retention times in human stomach.
Therapeutic effects of IPAP-FR on the ethanol-induced rat model
Finally, we compared the therapeutic effects of IPAP-FR and IPAP tablets in the etha-
nol-induced ulcer rat model. To establish the ethanol-induced ulcer model, 70 % ethanol 
was administrated to fasting rats. As shown in Table V, ethanol markedly increased hem-
orrhagic lesion (44.8 ± 3.3 mm2) in the stomach. As expected, post-treatment with the IPAP 
tablet or IPAP-FR (90 mg kg–1, p.o.) significantly ameliorated the gastric hemorrhagic lesion 
(14.6 ± 1.4 and 8.5 ± 1.1 mm2, respectively). More importantly, the IPAP-FR tablet (81.0 % 
inhibition) exhibited significantly higher healing effects than the IPAP tablet (67.4 % inhibi-
tion). These data suggest the superiority of the IPAP-FR tablet over the IPAP tablet owing 
to its prolonged therapeutic effect against gastric ulcer.
CONCLUSIONS
IPAP has favorable protective and therapeutic effects against ulcer damage in various 
gastric ulcer models. The IPAP-FR, a gastroretentive tablet of IPAP, was successfully developed 
by a floating system combination approach and showed improved properties in the ethanol- 
-induced ulcer model. Both IPAP and IPAP-FR are potentially attractive therapeutic options 
for treating gastric ulcer.
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Table V. Therapeutic effects of the IPAP-FR tablet or IPAP tablet on 70 % ethanol-induced gastric ulcers in rats
Treatment (p.o.) Dose (mg kg–1) Hemorrhagic lesion (mm2) Inhibition (%)
Vehicle 0 0 –
Ethanol 0 44.8 ± 3.3 0
IPAP tablet 90 0 –
IPAP- FR 90 0 –
Ethanol 
+ IPAP-tablet 90 14.6 ± 1.4a 67.4
+ IPAP- FR 90 8.5 ± 1.1a,b 81.0
Data are presented as means ± SEM (n = 5/group).
a p < 0.05 vs. the ethanol-induced group.
b p < 0.05 vs. the ethanol + IPAP tablet-treated group.
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